A decade of clinical data with vedolizumab: the past, present, and future
Vipul Jairath, Alessandro Armuzzi, Christian Agboton, Brian Bressler, Silvio Danese, Parambir S Dulai, Marlies Meyer, Itzel Romo Bautista, Raja Atreya, Brian G Feagan · 2026
Read A decade of clinical data with vedolizumab: the past, present, and future by Vipul Jairath, Alessandro Armuzzi, Christian Agboton, Brian Bressler, Silvio Danese, Parambir S Dulai, Marlies Meyer, Itzel Romo Bautista, Raja Atreya, Brian G Feagan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13201942.txt.
Description
Ten years of using one gut-selective biologic are reviewed in a 2026 narrative review by Vipul Jairath, focused on vedolizumab for inflammatory bowel disease. The article traces how treatment of ulcerative colitis and Crohn's disease changed over the decade, and where this antibody therapy fits among newer options.
Jairath and co-authors describe the shift from step-up treatment to early, target-driven strategies with endoscopic goals. Vedolizumab, the first approved drug blocking lymphocyte traffic into the gut, is assessed across that changing landscape of care. The review also weighs open problems, including how to sequence biologics and combine them, and points to decision-support tools as a promising direction.
Catalog record
| CREATOR | Vipul Jairath, Alessandro Armuzzi, Christian Agboton, Brian Bressler, Silvio Danese, Parambir S Dulai, Marlies Meyer, Itzel Romo Bautista, Raja Atreya, Brian G Feagan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |